Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 791 to 800 of 879 total matches.

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
.19,20 Fezolinetant can cause abdominal pain, diarrhea, insomnia, back pain, hot flushes, and hepatic ...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8   doi:10.58347/tml.2024.1697a |  Show IntroductionHide Introduction

Drugs for Vomiting Caused by Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 1993  (Issue 912)
cause no adverse effects, although rapid injection can cause intense genital or perineal pain. Mild ...
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Med Lett Drugs Ther. 1993 Dec 24;35(912):124-6 |  Show IntroductionHide Introduction

Acamprosate (Campral) for Alcoholism

   
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005  (Issue 1199)
has occurred in a few patients. Other infrequent adverse events include abdominal pain, nausea, vomiting ...
Acamprosate calcium (Campral - Forest) is now being marketed for oral use to maintain abstinence from alcohol. It has been used in France and other countries since 1989.
Med Lett Drugs Ther. 2005 Jan 3;47(1199):1-3 |  Show IntroductionHide Introduction

Alprazolam (Xanax, and others) Revisited

   
The Medical Letter on Drugs and Therapeutics • Jan 17, 2005  (Issue 1200)
lead to rebound anxiety or withdrawal symptoms (sweating, abdominal cramps, nausea, muscle pain ...
Alprazolam, a short-acting benzodiazepine, is one of the most widely prescribed drugs in the US. It is approved by the FDA for treatment of anxiety and panic disorder. An extended-release formulation, Xanax XR, which can be taken once a day, recently became available for panic disorder.
Med Lett Drugs Ther. 2005 Jan 17;47(1200):5-7 |  Show IntroductionHide Introduction

Menactra: A Meningococcal Conjugate Vaccine

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2005  (Issue 1206)
include headache, fatigue and malaise, in addition to pain, redness and induration at the site ...
The FDA has approved a conjugated polysaccharide vaccine, Menactra (Sanofi-Pasteur), for protection against disease caused by Neisseria meningitidis in people 11-55 years old, and the manufacturer has applied for approval for use in children 2 to 10 years old. An unconjugated meningoccocal polysaccharide vaccine (Menomune - Sanofi-Pasteur) has been licensed in the US since 1981.
Med Lett Drugs Ther. 2005 Apr 11;47(1206):29-31 |  Show IntroductionHide Introduction

Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006  (Issue 1226)
of injection site pain (both vaccines) and fever (Adacel) have been higher than with standard Td vaccines ...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine...
Med Lett Drugs Ther. 2006 Jan 16;48(1226):5-6 |  Show IntroductionHide Introduction

Insulin Detemir (Levemir), a New Long-Acting Insulin

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006  (Issue 1238)
, as with glargine, rates of nocturnal hypoglycemia have been lower with detemir than with NPH. 8,9 Mild pain can ...
Insulin detemir (Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus), the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting...
Med Lett Drugs Ther. 2006 Jul 3;48(1238):54-5 |  Show IntroductionHide Introduction

Two New Drugs for Renal Cell Carcinoma

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007  (Issue 1255)
Drugs for Pain — April 2007 Choice of Antibacterial Drugs — May 2007 issue 1255 Interleukin-2 ...
Sunitinib (Sutent - Pfizer) and sorafenib (Nexavar - Bayer), two oral tyrosine kinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma (RCC). Sunitinib is also approved for use in patients with gastrointestinal stromal tumor (GIST) who are not responding to or are intolerant of standard therapy with imatinib (Gleevec).
Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20 |  Show IntroductionHide Introduction

Paliperidone (Invega) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Mar 12, 2007  (Issue 1256)
) for Ulcerative Colitis Dermal Fillers Coming Soon in Treatment Guidelines: Drugs for Pain — April 2007 Choice ...
Paliperidone (Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic risperidone (Risperdal - Janssen), which is scheduled to lose its patent exclusivity in December 2007.
Med Lett Drugs Ther. 2007 Mar 12;49(1256):21-3 |  Show IntroductionHide Introduction

MoviPrep: A New Bowel Prep for Colonoscopy

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
of other PEG-based solutions. ADVERSE EFFECTS — Abdominal distension and pain, nausea, anal discomfort ...
MoviPrep (Salix) is a new polyethylene glycol (PEG)-based bowel cleansing preparation approved for use in adults prior to colonoscopy. It contains ascorbic acid, which acts as an additional cathartic and flavoring agent, and requires a lower volume of fluid (3 L compared to the traditional 4 L) than most other PEG products. HalfLytely is an FDA-approved 2-L PEG product, but it must be taken with bisacodyl.
Med Lett Drugs Ther. 2007 Jun 4;49(1262):47-8 |  Show IntroductionHide Introduction